The cost of pulmonary thromboembolism treatment

Bugra Coskuner M., ÖZTUNA F., BÜLBÜL Y., Ozsu S.

TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX, vol.68, no.3, pp.293-304, 2020 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 68 Issue: 3
  • Publication Date: 2020
  • Doi Number: 10.5578/tt.70104
  • Journal Name: TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, CAB Abstracts, EMBASE, MEDLINE, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.293-304
  • Karadeniz Technical University Affiliated: Yes

Abstract

Introduction: Primary aim of this study is to determine the financial burden of Vitamin K Antagonists (VKA), low molecular weight heparins (LMWH) and new oral anticoagulants (NOAC) which are used in the treatment of the pulmonary thromboembolism (PTE). Secondary aim is to show long term complications of the treatment options.